Cargando…

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

BACKGROUND: Recent studies have reported TIMs play an important role in tumors progression or regression, but the effect of TIMs in biliary tract cancer remains unclear. The aim of this study is to investigate the prognostic value of tumor infiltrating mast cells (TIMs) and its influence on gemcitab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bo, Xiaobo, Wang, Jie, Suo, Tao, Ni, Xiaoling, Liu, Han, Shen, Sheng, Li, Min, Wang, Yueqi, Liu, Houbao, Xu, Jiejie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863450/ https://www.ncbi.nlm.nih.gov/pubmed/29562907 http://dx.doi.org/10.1186/s12885-018-4220-1

Ejemplares similares

Tumor‐infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer
por: Wang, Jie, et al.
Publicado: (2018)

High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer
por: Bo, Xiaobo, et al.
Publicado: (2020)

Stathmin 1 expression predicts prognosis and benefits from adjuvant chemotherapy in patients with gallbladder carcinoma
por: Bo, Xiaobo, et al.
Publicado: (2017)

Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010‐2016
por: Wang, Jie, et al.
Publicado: (2019)

Laparoscopic common bile duct exploration in patients with previous abdominal biliary tract operations
por: Li, Min, et al.
Publicado: (2020)

LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma
por: Shen, Sheng, et al.
Publicado: (2019)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

The impact of preoperative biliary drainage on postoperative outcomes in patients with malignant obstructive jaundice: a retrospective analysis of 290 consecutive cases at a single medical center
por: Gao, Zhihui, et al.
Publicado: (2022)

Low immune index correlates with favorable prognosis but with reduced benefit from chemotherapy in gallbladder cancer
por: Wang, Jie, et al.
Publicado: (2019)

Effect of midkine on gemcitabine resistance in biliary tract cancer
por: Lu, Yongliang, et al.
Publicado: (2018)

Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101)
por: Fujiwara, Yutaka, et al.
Publicado: (2015)

Tumor-infiltrating IL-17A(+) cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer
por: Wang, Zewei, et al.
Publicado: (2020)

Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer
por: Zhao, Qing, et al.
Publicado: (2015)

Intratumoral PD-1(+)CD8(+) T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer
por: Yu, Kuan, et al.
Publicado: (2022)

Potential therapeutic value of primary tumor resection in ampullary cancer patients with distant metastases at initial diagnosis: a population-based study
por: Wang, Jie, et al.
Publicado: (2018)

Efficacy Analysis of Adjuvant Chemotherapy with Gemcitabine Plus Platinum or S-1 in Biliary Tract Carcinoma: A Multi-Center Retrospective Study
por: Gao, Huan, et al.
Publicado: (2021)

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Adjuvant treatment in biliary tract cancer
por: Palloni, Andrea, et al.
Publicado: (2019)

Adjuvant therapy of biliary tract cancers
por: Kefas, Joanna, et al.
Publicado: (2023)

Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study
por: Siebenhüner, Alexander R., et al.
Publicado: (2018)

Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
por: Feng, Kaichao, et al.
Publicado: (2020)

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
por: André, T, et al.
Publicado: (2008)

BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer
por: Nakashima, Shinsuke, et al.
Publicado: (2015)

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
por: Park, Joon Oh, et al.
Publicado: (2015)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

Adjuvant Radio-chemotherapy for extrahepatic biliary tract cancers
por: Bonet Beltrán, Marta, et al.
Publicado: (2011)

Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone
por: Murata, Akihiro, et al.
Publicado: (2013)

A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan
por: Tsukiyama, Ikuto, et al.
Publicado: (2016)

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013)

Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction
por: Shibata, Takashi, et al.
Publicado: (2016)

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2017)

MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine
por: Wensheng, Liu, et al.
Publicado: (2019)

The Clinical Benefit of Percutaneous Transhepatic Biliary Drainage for Malignant Biliary Tract Obstruction
por: Nikolić, Ivan, et al.
Publicado: (2022)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020)

Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)
por: Toyoda, Masanori, et al.
Publicado: (2014)

Gemcitabine and S-1 Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer: A Retrospective Study
por: Mita, Kazuhito, et al.
Publicado: (2010)

Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines
por: Sakamoto, Yasunari, et al.
Publicado: (2019)

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
por: Wu, Chiao-En, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_umvohmvcmg0cdnj8f5a8dvg8fl